Email: cspc@cspc.cn
News
April 23, 2026
Share:
Previous: VOLUNTARY ANNOUNCEMENT - SYS6051 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Next: VOLUNTARY ANNOUNCEMENT - Phase Ib/III Clinical Study of Sirolimus for Injection (Albumin-Bound) (HB1901) for the Treatment of Advanced Malignant Perivascular Ep
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
